Author

Peter Vis

Observed names: P Vis, P W Vis, P. Vis, P.W. Vis, Peter W. Vis, VIS, Peter, Vis, Peter

Institutions: Bayer (Germany), European University Institute

Observed institutions: Leiden University, Harvard University, Janssen (Belgium), Georgetown University, University of Michigan, L&S Consulting (South Africa), Servier (United Kingdom), Centre for Human Drug Research, Hospital de Santa Maria, New York University, Bayer (Germany), European University Institute, KU Leuven

ORCID: 0000-0003-3701-3270

Observed ORCID: 0000-0003-3701-3270

OpenAlex ID: A5081908884

Towards a Climate-Neutral Europe

2019 · Jos Delbeke, Peter Vis · Routledge eBooks · 85

Population Pharmacokinetics of Bedaquiline (TMC207), a Novel Antituberculosis Drug

2014 · Sarah C. McLeay, Peter Vis, et al. · Antimicrobial Agents and Chemotherapy · 79

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

2009 · Stéphane Blanche, Rosa Bologna, et al. · AIDS · 52

Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside Reverse-Transcriptase Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients

2010 · T N Kakuda, J R Wade, et al. · Clinical Pharmacology & Therapeutics · 49

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII : lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

2017 · D. Garmann, S. McLeay, et al. · Haemophilia · 39

PDF

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

2012 · Thomas Kakuda, Vanitha Sekar, et al. · AIDS Research and Treatment · 30

PDF

Characterization of the pharmacodynamics of several antiepileptic drugs in a direct cortical stimulation model of anticonvulsant effect in the rat.

1994 · A Hoogerkamp, P W Vis, et al. · Journal of Pharmacology and Experimental Therapeutics · 30

The EU Emissions Trading System

2019 · Damien Meadows, Peter Vis, et al. · Routledge eBooks · 23

Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral‐naïve, HIV‐1‐infected patients in ECHO and THRIVE

2010 · HM Crauwels, E van Schaick, et al. · Journal of the International AIDS Society · 23

PDF

Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop

2014 · Klaus Romero, Vikram Sinha, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 18

Pharmacokinetics and short-term safety of the selective NOS inhibitor 2-iminobiotin in asphyxiated neonates treated with therapeutic hypothermia

2019 · Laurent M. A. Favié, Cacha M. P. C. D. Peeters-Scholte, et al. · Pediatric Research · 17

PDF

Pharmacokinetic (PK) and pharmacodynamic analyses of once‐ and twice‐daily darunavir/ritonavir (DRV/r) in the ODIN trial

2010 · V Sekar, G De La Rosa, et al. · Journal of the International AIDS Society · 16

PDF

Population pharmacokinetic drug–drug interaction pooled analysis of existing data for rifabutin and HIV PIs

2016 · Stefanie Hennig, Elin M. Svensson, et al. · Journal of Antimicrobial Chemotherapy · 15

Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach

2019 · Alexander Solms, Alfonso Iorio, et al. · Clinical Pharmacokinetics · 14

PDF

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged≥3 to <12 Years

2015 · A Brochot, TN Kakuda, et al. · CPT Pharmacometrics & Systems Pharmacology · 14

PDF

Reforming ESG: a European and Global South perspective

2025 · Simone Borghesi, Valeria Costantini, et al. · Environment and Development Economics · 13

PDF

A Phase IIa Clinical Trial of 2-Iminobiotin for the Treatment of Birth Asphyxia in DR Congo, a Low-Income Country

2020 · Thérèse Biselele, Jephté Bambi, et al. · Pediatric Drugs · 9

Population pharmacokinetic–pharmacodynamic modelling of S 15535, a 5-HT1A receptor agonist, using a behavioural model in rats

2001 · Peter Vis, Oscar Della Pasqua, et al. · European Journal of Pharmacology · 8

Addressing Carbon Leakage under the EU ETS

2024 · Damien Meadows, Beatriz Yordi, et al. · Routledge eBooks · 6

Neuroprotection after cardiac arrest with 2-iminobiotin: a single center phase IIa study on safety, tolerability, and pharmacokinetics

2023 · M. M. Admiraal, D. C. Velseboer, et al. · Frontiers in Neurology · 4

EU Climate policy as a driver of change

2020 · Jos Delbeke, Peter Vis · Renewable energy law and policy review · 4

A way forward for a carbon border adjustment mechanism by the EU

2020 · Jos Delbeke, Peter Vis · Cadmus - EUI Research Repository (European University Institute) · 4

PDF

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV‐1‐Infected, Treatment‐Experienced Children and Adolescents in PIANO

2016 · Thomas N. Kakuda, Anne Brochot, et al. · The Journal of Clinical Pharmacology · 4

1075 Pharmacokinetic-pharmacodynamic (pk-pd) Analyses of Tmc435 in Treatment-naive Hepatitis C (hcv)-infected Patients in the Opera-1 Study

2010 · V. Sekar, P. Vis, et al. · Journal of Hepatology · 4

Pharmacokinetics, Safety, and Dialyzability of Gadoquatrane in Patients With Impaired Renal Function

2025 · Tommaso Fadini, Gabriele Sutter, et al. · Investigative Radiology · 3

Works count: 55

Citation count: 590

H-index: 14

I10-index: 16